Overview

This trial is active, not recruiting.

Condition esophageal cancer
Treatments conformal 3d radiotherapy with " eni "-type prophylactic irradiation of the lymph node, boost, chemotherapy: folfox 4
Phase phase 2/phase 3
Sponsor Centre Georges Francois Leclerc
Collaborator National Cancer Institute, France
Start date March 2011
End date October 2016
Trial size 252 participants
Trial identifier NCT01348217, 0291-1crgi09

Summary

Exclusive concomitant radiochemotherapy (RCT) at a dose of 50 Gy delivered over 5 weeks, according to the RTOG 85-01 protocol, has led to improved 5-year survival in 25% of patients, whereas no patients survived for 5 years using radiotherapy alone for patients with esophageal cancer. Surgery, even when combined with preoperative RCT, also gives disappointing results for locally advanced tumors, which casts serious doubts on the usefulness of preoperative radiotherapy. By varying the fractionation schedule, the length of treatment or the radiotherapy volumes, it has become possible to obtain levels of loco-regional relapse of around 35 to 45%. After reviewing the results for loco-regional relapse according to the dose of radiation and the recommended radiotherapy volumes, we aimed to investigate why increasing the dose of radiation has no impact in esophageal cancers. Although INT-0123 phase III trial showed no benefit of dose escalation in esophageal cancer, some issues remain unclear as most of the patients who died in the experimental arm were treated above 50Gy. Moreover, only the tumor was treated up to 64Gy while involved nodes were not considered for dose escalation in this trial. In the RTOG 85-01phase III trial, an elective nodal irradiation from subclavicular fossa up to the esophagogastric junction was performed with a 2D technique, delivering 30Gy which could be considered as not appropriate.

In this randomized phase II/III trial, we aim to test an exclusive concomitant chemoradiotherapy for patients with non resectable esophageal cancer with a dose escalation up to 66Gy on the primary tumor as well as the involved nodes using a 3D conformal technique combined with a 40 Gy elective nodal irradiation on lymph node stations (as defined by the RTOG) with a risk of microscopic involvement ≥ 20%.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph nodes: Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction) Boost 10 Gy in 5 fr: PTV = +1cm. Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)
conformal 3d radiotherapy with " eni "-type prophylactic irradiation of the lymph node
40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
boost
Boost 10 Gy in 5 fr, PTV = +1cm.
chemotherapy: folfox 4
6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
(Experimental)
Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph nodes: 40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction) Boost 26 Gy in 13 fr: PTV = +1cm. Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43).
conformal 3d radiotherapy with " eni "-type prophylactic irradiation of the lymph node
40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
boost
Boost 26 Gy in 13 fr, PTV = +1cm.
chemotherapy: folfox 4
6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.

Primary Outcomes

Measure
Evaluate the rate of acute toxicity leading to cessation or temporary interruption of treatment of more than a total of 14 days or of 7 consecutive days during the whole treatment.
time frame: end of phase II (january 2014)
Evaluate the rate of completes endoscopic response at 3 months
time frame: for each patient 3 months after the end treatment
Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement)
time frame: after the end of phase III in january 2015 (anticipated)

Secondary Outcomes

Measure
Evaluate adherence
time frame: every 3 months until the end of phase II (january 2014)
Evaluate acute toxicity at 3 months
time frame: for each patient 3 months after the end treatment
Evaluate death due to toxicity
time frame: each month during all the study
Evaluate quality of life (QLQ-C30 [annex n° 2] + OG25 [annex n° 3])
time frame: after the completion of phase II (january 2014)
Compare according to treatment arm :Quality of life (QLQ-C30 [annex n° 2] + OG 25 [annex n° 3])
time frame: after the completion of phase III (january 2015-anticpated)
Compare according to treatment arm :Overall survival
time frame: after the completion of phase III (january 2015-anticpated)
Compare according to treatment arm :Disease-free survival
time frame: after the completion of phase III (january 2015-anticpated)
Compare according to treatment arm :Acute and late toxicity according to the CTCAE version 3.0 scale
time frame: after the completion of phase III (january 2015-anticpated)
Compare according to treatment arm :The number of palliative interventions, the time to the first palliative intervention
time frame: after the completion of phase III (january 2015-anticpated)
Compare according to treatment arm :The rate of dysphagia according to Atkinson's criteria
time frame: after the completion of phase III (january 2015-anticipated)
Compare according to treatment arm :Survival without local recurrence in responders
time frame: after the completion of phase III (january 2015-anticipated)
Compare according to treatment arm :Progression-free survival in non-responding patients
time frame: after the completion of phase III (january 2015-anticipated)
Evaluation of the post-operative morbi-mortalities
time frame: after the completion of phase III (january 2015-anticipated)

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1. Age> or = 18 and < 75 ans 2. WHO Status 0, 1 and 2 3. Enteral or parenteral feeding (> or = 1500 KCal) planned before the start of treatment 4. Histologically proven carcinoma of the oesophagus 5. Histological Types: adenocarcinomas and epidermoid carcinomas 6. T3, N0-N1-N2-N3, M0 (TNM version 7) 7. T1-T2, N0-N1-N2-N3, M0 with a contra-indication for surgery (TNM version 7) 8. Absence of trachea-oesophageal fistula 9. Written informed consent 10. Woman under appropriate contraception 11. Patient able to understand and complete, with help if necessary, a quality of life questionnaire Exclusion Criteria: 1. Evolutive heart failure or myocardial necrosis for less than 6 months 2. Myocardial infarction of more than 6 months with ischemic sequelae on myocardial scintigraphy. 3. Patient cannot absorb at least 1500kcal/j before and/or during treatment 4. Left heart failure. 5. Stage II to IV arteriopathy in the Leriche and Fontaine classification 6. Creatinine > or = 1.25x N 7. PNN < 1,5.109 /l 8. Platelets < 100. 109 /l 9. Albumin < 30g/l 10. TP < 60% without anticoagulant 11. VEMS < 1l 12. History of cancer (except baso-cellular cutaneous epithelioma or in situ epithelioma of the cervix) that has relapsed in the 5 years preceding recruitment for the trial 13. Patient already enrolled in another therapeutic trial with an experimental molecule 14. Women who are pregnant or likely to be so, or who are breastfeeding 15. People who are in custody or under guardianship 16. Impossibility to adhere to the medical follow up for the trial for geographical,social or psychiatric reasons. 17. Presence of a history of radiotherapy to the chest or upper abdomen for another tumour 18. Peripheral neuropathy > or = grade 1 (CTC v3.0)

Additional Information

Official title Prodige 26: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
Principal investigator Gilles Créhange, MD
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Centre Georges Francois Leclerc.